Autologous stem cell transplantation (ASCT) emerges as a therapeutic strategy following remission in adult acute leukemia (AL). It offers advantages over allogeneic hematopoietic stem cell transplantation (allo-HSCT), including independence from donor availability, absence of graft-versus-host disease (GVHD), and a reduced risk of transplant-related mortality. Furthermore, when juxtaposed with the extended regimens of consolidation chemotherapy, ASCT stands out by markedly abbreviating treatment duration, alleviating the economic strain on patients, and enhancing their overall quality of life. Despite these benefits, the adoption of ASCT among adult AL patients in China remains disproportionately low. To enhance clinical physicians' understanding of the role and position of ASCT in AL management and to improve the clinical efficacy of ASCT, it is urgent to establish a consensus among experts on ASCT for adult acute leukemia in our nation.
Keyphrases
- stem cell transplantation
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- high dose
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- primary care
- acute myeloid leukemia
- prognostic factors
- bone marrow
- low dose
- cell therapy
- squamous cell carcinoma
- systemic lupus erythematosus
- radiation therapy
- risk factors
- clinical practice
- childhood cancer
- platelet rich plasma
- locally advanced
- rectal cancer